Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Sustained Delivery of Anti-VEGF Agents: Gene Therapy for the Treatment of Neovascular AMD

By: Arshad M. Khanani, MD, MA; and Christina Y. Weng, MD, MBA

Webinar Credits: .75

Arshad M. Khanani, MD, MA, discusses with Christina Y. Weng, MD, MBA, how trial results differ from real-world experience with anti-VEGF injections of patients with neovascular age-related macular degeneration, and how gene therapy may fill various unmet needs in treating this disease.

Expiration Date: Thursday, September 30, 2021
Release Date: September 2020

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the differences in real-world clinical outcomes with those from prospective clinical trials.
  • Develop individualized treatment regimens for patients with AMD who may benefit from treatments with longer duration.
  • Discuss newer compounds in development or recently approved that are designed to improve visual outcomes while decreasing treatment burden.

 

Accreditation and Designation Statement

Provided by Evolve Medical Education 

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

 

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates

Clinical Associate Professor
University of Nevada
Reno School of Medicine
Reno, Nevada

Christina Y. Weng, MD, MBA
Associate Professor of Ophthalmology
Baylor College of Medicine
Houston, Texas

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Arshad M. Khanani, MD, MA; and or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Aerpio, Allegro, Allergan, Graybug, Genentech, Gyroscope, Kodiak, Notal Vision, Novartis, Opthea, Orbit BioMedical, Oxurion, Polyphotonix, Recens Medical, and Regenexbio. Grant/Research Support: Advernum, Aerpio, Allergan, Gemini, Genentech, Graybug, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, Recens Medical, and Regenxbio. Speaker’s Bureau:  Allergan, Genentech, and Novartis.

Christina Y. Weng, MD, MBA; and/or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Alimera Sciences, Allergan, and Novartis

The staff and planners at Evolve Medical Education have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech.

Pretest

  • a. 1b. 2c. 3d. 4e. 5

Video Resources

Next

Test

Instructions

Step 1 of 2

  • a. 1b. 2c. 3d. 4e. 5
  • AgreeNeutralDisagree
    Develop individualized treatment regimens for patients with AMD who may benefit from treatments with longer duration.
    Discuss newer compounds in development or recently approved that are designed to improve visual outcomes while decreasing treatment burden.
Back